Keyphrases
Diabetic Kidney Disease
100%
Breakthrough Therapy
100%
Health Systems
37%
Drug Costs
25%
Kidney Failure
25%
Payers
25%
Cost-effectiveness
12%
Clinical Efficacy
12%
Patient Preference
12%
Effective Therapy
12%
Expanded Access
12%
Federal Agencies
12%
Community Outreach
12%
Cardiovascular Disease
12%
Access to Care
12%
Kidney
12%
Cardiovascular Risk
12%
Public Health Risk
12%
Collaborative Model
12%
Community Groups
12%
Cardiovascular Events
12%
Patients with Diabetes
12%
Angiotensin Receptor Blockers
12%
Healthcare Professionals
12%
Treatment Standards
12%
System Support
12%
Out-of-pocket
12%
Receptor Agonist
12%
Communication Technologies
12%
Family Community
12%
Highly Effective
12%
Value-based Care
12%
Premature Death
12%
Pharmaceutical Industry
12%
A1 Receptor
12%
Glucagon-like
12%
Reimbursement Rates
12%
Non-steroidal
12%
Personal Healthcare
12%
Mineralocorticoid Receptor Antagonists
12%
Interdisciplinary Communication
12%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
12%
Patient Priorities
12%
Interdisciplinary Model
12%
Angiotensin-converting Enzyme Inhibitor (ACEi)
12%
Patient's Family
12%
Recommended Screening
12%
Professional Healthcare
12%
Affordable Drugs
12%
Medicine and Dentistry
Diabetic Nephropathy
100%
Health Care
50%
Renal Failure
25%
Cardiovascular System
12%
Cardiovascular Risk
12%
Cost-Effectiveness Analysis
12%
Public Health
12%
Prematurity
12%
Cardiovascular Disease
12%
Patient with Diabetes
12%
Angiotensin Receptor Antagonist
12%
ACE Inhibitor
12%
Patient Preference
12%
Glucagon-Like Peptide-1 Agonist
12%
Mineralocorticoid Antagonist
12%
Sodium Glucose Cotransporter 2 Inhibitor
12%